Archives

  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10

    • 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)pheny...

    2026-01-16

    3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide: Exploring H+,K+-ATPase Inhibition and the Gut–Liver–Brain Axis in Gastric Acid Research

    Introduction

    The intricate regulation of gastric acid secretion is central to the study of gastrointestinal physiology and pathology. Pharmacological modulation of this process is vital not only for understanding peptic ulcer disease models but also for elucidating the complex interplay between gut, liver, and brain health. 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide (SKU: A2845) stands out as a highly selective H+,K+-ATPase inhibitor with robust antiulcer activity, offering researchers a powerful tool for dissecting gastric acid-related disorders and proton pump inhibition pathways. While previous studies have focused on this compound's reliability in antiulcer activity studies and protocol optimization, this article delves deeper—exploring its potential as a model agent for investigating the gut–liver–brain axis, an emerging frontier in gastroenterological and neuroinflammatory research.

    The Scientific Foundation: H+,K+-ATPase and Its Role in Gastric Acid Secretion

    H+,K+-ATPase, commonly known as the gastric proton pump, is essential for acidifying the stomach by exchanging intracellular hydrogen ions (H+) for extracellular potassium ions (K+). Its inhibition is a cornerstone in the study of gastric acid secretion, antiulcer drug development, and pathophysiological modeling of gastric acid-related disorders. The development of potent and selective inhibitors such as 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide has revolutionized the field, enabling precise experimental control over acid secretion in both in vitro and in vivo systems.

    Key Physicochemical and Pharmacological Properties

    • IC50 for H+,K+-ATPase inhibition: 5.8 μM
    • IC50 for histamine-induced acid formation: 0.16 μM
    • Molecular weight: 345.42
    • Chemical formula: C17H19N3O3S
    • Solubility: ≥17.27 mg/mL in DMSO; insoluble in water and ethanol
    • Purity: ~98%, validated by HPLC and NMR

    This high selectivity and potency make A2845 a vital antiulcer agent for research, particularly in dissecting the H+,K+-ATPase signaling pathway and its downstream physiological effects.

    Mechanistic Insights: Proton Pump Inhibition and Beyond

    Classical Mechanism in Gastric Acid Secretion

    3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide exerts its primary action by binding to the transmembrane domain of H+,K+-ATPase, stabilizing the enzyme in an inactive conformation. This blockade prevents the exchange of H+ and K+ ions, leading to a marked reduction in gastric acid secretion. This mechanism is particularly valuable in peptic ulcer disease models, where acid suppression is pivotal for studying mucosal defense, ulcer healing, and the efficacy of antiulcer agents.

    Notably, the compound demonstrates exceptional potency in blocking histamine-stimulated acid formation—a key pathway in gastric acid secretion research. This enables researchers to model both basal and stimulated acid secretion states with high fidelity.

    Emerging Role in Gut–Liver–Brain Axis Research

    Beyond its classical applications, recent advances have highlighted the interplay between gastric acid secretion, gut microbiota, liver inflammation, and neuroinflammation—a network known as the gut–liver–brain axis. Disruption of this axis is implicated in complex disorders such as hepatic encephalopathy, where systemic inflammation and altered microbiota composition affect brain function (see Kong et al., 2025).

    In this context, using a potent and selective gastric acid secretion inhibitor like A2845 can provide a controlled platform for:

    • Modulating stomach pH to study downstream effects on gut microbiota composition
    • Assessing how altered acid secretion impacts liver inflammation and neuroinflammatory markers
    • Modeling the pharmacodynamic interactions within the gut–liver–brain axis

    These applications set the stage for advanced research well beyond traditional antiulcer activity studies.

    Integrating Recent Neuroinflammation Research: Bridging Gastroenterology and Neuroscience

    The recent European Journal of Neuroscience study by Kong and colleagues (2025) provides a compelling example of how gut-targeted interventions can impact neuroinflammation in chronic hepatic encephalopathy models. Using [18F]PBR146 PET/CT imaging, the study demonstrated that modulating gut microbiota—via Bifidobacterium or fecal microbiota transplantation—affects neuroinflammatory signatures in the brain. Although direct acid inhibition was not assessed, the research underscores the value of manipulating gut physiology to study systemic and neural outcomes.

    By leveraging 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide, researchers can extend this paradigm: precisely controlling gastric acid secretion to interrogate its downstream impact on microbiome composition, liver biomarkers, and ultimately, neuroinflammation. This approach opens new avenues for modeling the gut–liver–brain axis in both health and disease.

    Comparative Analysis with Alternative Methods and Products

    Distinct Advantages Over Conventional Proton Pump Inhibitors and Assay Standards

    While earlier articles—such as "Optimizing Gastric Acid Secretion Research with 3-(quinolin-4-ylmethylamino)..."—focus primarily on protocol precision and troubleshooting for antiulcer assays, and "Applied Advances in H+,K+-ATPase Inhibitor Research..." highlight workflow reproducibility, this article uniquely positions A2845 as a bridge between classic gastric acid research and next-generation gut–brain studies.

    Key differentiators include:

    • Broader Systemic Modeling: A2845 enables researchers to link gastric acid modulation with systemic inflammation and neuroinflammatory endpoints, unlike standard protocols focused solely on gastric mucosal outcomes.
    • Superior Selectivity: With a sub-micromolar IC50 for histamine-induced acid secretion, A2845 provides more precise pharmacological control compared to older proton pump inhibitors.
    • Validated Analytical Purity: High HPLC and NMR purity ensures minimal off-target effects in complex in vivo models.

    Moreover, unlike the comparative and troubleshooting focus in "H+,K+-ATPase Inhibition in Gastric Acid Secretion Research", this article emphasizes the translational potential of acid inhibition for cross-disciplinary research—particularly in models where gastrointestinal, hepatic, and neural axes intersect.

    Advanced Applications: Modeling the Gut–Liver–Brain Axis and Beyond

    Experimental Platforms

    Utilizing 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide (available from APExBIO) as a gastric acid secretion inhibitor allows for the development of sophisticated experimental platforms, including:

    • Gastric acid–microbiome interaction models: Assess how reduced acidity alters gut microbial diversity and function, using metagenomics or metabolomics workflows.
    • Gut–liver axis studies: Explore how acid suppression influences hepatic biomarkers, inflammation, and susceptibility to liver injury in animal models.
    • Gut–brain axis investigations: Combine A2845-mediated acid inhibition with neuroimaging (e.g., [18F]PBR146 PET/CT) to monitor neuroinflammation, as demonstrated in the cited reference (Kong et al., 2025).

    Potential in Drug Discovery and Translational Research

    The distinct pharmacological profile of A2845 positions it as an ideal reference compound in screening for novel antiulcer agents, validating ic omeprazole analogs, or dissecting the H+,K+-ATPase signaling pathway in pathophysiological states. Its robust solubility in DMSO and high purity further facilitate its use in high-throughput screening or in complex, multi-organ system studies.

    Practical Considerations for Laboratory Use

    Handling and Storage

    For optimal stability, A2845 should be stored at -20°C and protected from prolonged exposure to ambient conditions. Given its insolubility in water and ethanol but high solubility in DMSO (≥17.27 mg/mL), researchers should prepare concentrated stock solutions and avoid long-term storage in solution form. This ensures reliability across repeated experiments and minimizes batch-to-batch variability.

    Purity Verification and Analytical Confidence

    Each lot of A2845 is supplied with approximately 98% purity, confirmed by HPLC and NMR analyses. This level of analytical confidence is critical when modeling subtle physiological or pharmacodynamic changes, particularly in multi-system models involving the gut–liver–brain axis.

    Conclusion and Future Outlook

    3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide represents a new standard for mechanistic gastric acid secretion inhibitor research, offering robust antiulcer activity, exceptional selectivity, and cross-disciplinary utility. By extending its application beyond conventional antiulcer models to encompass the gut–liver–brain axis, researchers can unlock novel insights into systemic inflammation, neuroinflammation, and the complex crosstalk between gastrointestinal and neural systems.

    As research continues to unravel the connections between gastric physiology, microbiota, liver function, and brain health, agents like A2845—available through APExBIO—will be indispensable tools for pioneering studies at the interface of gastroenterology, hepatology, and neuroscience.

    References